Profile data is unavailable for this security.
About the company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
- Revenue in USD (TTM)0.00
- Net income in USD-45.86m
- Incorporated2011
- Employees26.00
- LocationTrevi Therapeutics Inc195 CHURCH STREET, 16TH FLOORNEW HAVEN 06510United StatesUSA
- Phone+1 (203) 304-2499
- Fax+1 (203) 304-2434
- Websitehttps://www.trevitherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Septerna Inc | 22.05m | -58.81m | 1.23bn | 75.00 | -- | 3.16 | -- | 55.85 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.25bn | 73.00 | -- | 5.69 | -- | 197.52 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.30bn | 54.00 | -- | 5.37 | -- | 428.91 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.31bn | 147.00 | 71.52 | 4.50 | 44.63 | 7.20 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Azenta Inc | 594.95m | 28.69m | 1.32bn | 3.00k | 45.77 | 0.768 | 15.43 | 2.22 | 0.6252 | -1.26 | 12.98 | 37.26 | 0.2891 | 4.03 | 4.00 | 198,317.70 | 1.39 | -0.3901 | 1.57 | -0.4328 | 44.59 | 45.32 | 4.82 | -1.73 | 2.61 | -- | 0.00 | -- | 3.55 | 8.85 | 200.38 | -- | -3.24 | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.33bn | 69.00 | -- | 2.60 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.33bn | 26.00 | -- | 7.03 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| Kodiak Sciences Inc | 0.00 | -217.34m | 1.35bn | 123.00 | -- | 49.37 | -- | -- | -4.12 | -4.12 | 0.00 | 0.447 | 0.00 | -- | -- | 0.00 | -73.58 | -33.79 | -82.91 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| Intellia Therapeutics Inc | 57.53m | -445.81m | 1.37bn | 403.00 | -- | 1.84 | -- | 23.90 | -4.27 | -4.27 | 0.5488 | 6.46 | 0.0548 | -- | 5.78 | 142,749.40 | -42.49 | -33.78 | -46.95 | -37.16 | -- | -- | -774.94 | -790.71 | -- | -- | 0.00 | -- | 59.55 | 6.07 | -7.86 | -- | -3.19 | -- |
| Novavax Inc | 1.06bn | 341.75m | 1.41bn | 952.00 | 4.84 | -- | 3.75 | 1.33 | 1.80 | 1.80 | 6.29 | -0.9643 | 0.7362 | 7.87 | 16.49 | 1,118,331.00 | 23.63 | -39.12 | 53.33 | -248.97 | 91.82 | -- | 32.10 | -67.41 | 2.24 | 17.15 | 2.66 | -- | -30.65 | 105.39 | 65.60 | -- | 47.71 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.42bn | 130.00 | -- | 5.67 | -- | 94.48 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Alvotech SA | 573.35m | 69.50m | 1.45bn | 1.01k | 22.17 | -- | 13.76 | 2.52 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.45bn | 61.00 | -- | 16.48 | -- | 23.18 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| AnaptysBio Inc | 169.47m | -84.63m | 1.47bn | 136.00 | -- | -- | -- | 8.67 | -2.82 | -2.82 | 5.70 | -1.07 | 0.4004 | -- | 3.86 | 1,246,081.00 | -19.99 | -19.96 | -22.14 | -21.08 | -- | -- | -49.94 | -200.59 | -- | -- | 1.10 | -- | 432.03 | 62.73 | 11.24 | -- | -14.96 | -- |
Data as of Feb 13 2026. Currency figures normalised to Trevi Therapeutics Inc's reporting currency: US Dollar USD
35.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 8.07m | 6.63% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.60m | 4.60% |
| Viking Global Investors LPas of 30 Sep 2025 | 5.13m | 4.21% |
| Marshall Wace LLPas of 31 Dec 2025 | 4.58m | 3.76% |
| AllianceBernstein LPas of 30 Sep 2025 | 4.29m | 3.53% |
| Rubric Capital Management LPas of 31 Dec 2025 | 3.77m | 3.09% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 3.30m | 2.71% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 3.08m | 2.53% |
| Octagon Capital Advisors LPas of 30 Sep 2025 | 2.82m | 2.31% |
| Eventide Asset Management LLCas of 31 Dec 2025 | 2.62m | 2.15% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
